The management of rheumatoid arthritis (RA) has significantly improved, but a substantial number of patients still experience ...

Background Pain and fatigue are among the most debilitating symptoms of systemic sclerosis (SSc), severely impairing quality ...

Background Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs are used in patients with psoriatic arthritis (PsA), but few studies directly compare their clinical ...

Flow chart for GC replacement continuation according to the ESE/ES guidelines .20 21 Conversion factor for cortisol: 1 nmol/L=0.036 µg/dL. GC, glucocorticoid. ES, Endocrine Society; ESE, European ...

Objectives The impact of body mass index (BMI) on cardiovascular risk in rheumatoid arthritis (RA) is unclear. RA characteristics may influence the association between BMI and risk. Disease activity, ...

Objectives This post hoc analysis assessed speed, magnitude and maintenance of pain improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib and methotrexate ...

Objectives To investigate the impact of disease activity and treatment with disease-modifying antirheumatic drugs (DMARDs) on all-cause mortality in patients with rheumatoid arthritis and prevalent ...

The cellular composition and underlying spatiotemporal transformation processes of subchondral bone in osteoarthritis (OA) remain unknown. Herein, various cell subsets from tibial plateau of patients ...

Objectives To integrate published single-cell RNA sequencing (scRNA-seq) data and assess the contribution of synovial fibroblast (SF) subsets to synovial pathotypes and respective clinical ...

Objective To study the pathophysiological differences of EGPA and IgG 4-related disease (RD) by clarifying their clinical, pathological and immunological features. Methods Clinical and pathological ...

Objectives Gout, as the most prevalent form of inflammatory arthritis, necessitates the use of animal models to investigate the molecular mechanisms involved in its development. Therefore, our ...

Objectives This 1-year long-term extension (LTE) study (NCT04451772) followed the 48-week phase 2 SLEek study (NCT03978520) that evaluated upadacitinib (a Janus kinase inhibitor) alone or combined ...